The SPRINT trial limited enrollment to PD-L1 expression > 50%, but approximately 30% of patients had high PD-L1 expression; therefore, a significant proportion of LA-NSCLC patients were excluded21. The gene discussed is CD274; the disease is non-small cell lung carcinoma.